John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
John C. Byrd,Peter Hillmen,Paolo Ghia,Arnon P. Kater,Asher Chanan-Khan,Richard R. Furman,Susan O'Brien,Mustafa Nuri Yenerel,Árpád Illés,Neil E. Kay,Jose Antonio Garcia Marco,Anthony R. Mato,John F. Seymour,Stéphane Leprêtre,Stephan Stilgenbauer,Tadeusz Robak,Priti Patel,Kara Higgins,Sophia Sohoni,Wojciech Jurczak +19 more
TL;DR: A retrospective study assessed the impact of vaccination on rates of herpes zoster in patients with CLL using data from the Veterans Administration Central Cancer Registry and found patients infected with herpesZoster were younger and more likely to receive treatment for their CLL.
43
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
TL;DR: The current knowledge of the metabolism of common anticoagulants and how they may interact with ibrutinib is reviewed.
43
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
C. H. Hui,K Y Goh,Deborah L. White,Susan Branford,Andrew Grigg,John F. Seymour,Y L Kwan,Sonya Walsh,R Hoyt,A Trickett,B Rudzki,David D.F. Ma,L B To,Timothy P. Hughes +13 more
TL;DR: In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34+ cell yields are significantly improved when imatinIB is temporarily withheld.
42
Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
TL;DR: The present study confirms the previously reported dismal prognosis of t(14;18)-associated ALL and identifies an extremely close association between the t( 14;18) and the t (8;9), with the latter translocation found only in the presence of the former.
42
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement
Tarec Christoffer El-Galaly,Chan Yoon Cheah,Martin Hutchings,N. G. Mikhaeel,Kerry J. Savage,Laurie H. Sehn,Sally F. Barrington,Jakob Werner Hansen,Mette Østergaard Poulsen,Daniel J. Smith,Kirsty Rady,Karen Juul Mylam,Thomas Stauffer Larsen,Staffan Holmberg,Maja Bech Juul,Sabrina Cordua,Michael Roost Clausen,Kristina Buchardi Jensen,Martin Bøgsted,Hans Erik Johnsen,John F. Seymour,Joseph M. Connors,Peter D. Brown,Diego Villa +23 more
TL;DR: Because involvement of the uterus by DLBCL appears to be associated with a high risk of SCNS, those patients should be considered for CNS staging and prophylaxis, but more studies are needed to determine whether the increased risk of secondary CNS involvement also applies to women with localized reproductive organDLBCL.
42